LOS ANGELES, CA - April 17, 2026 (NEWMEDIAWIRE) - Cancer treatment is entering a phase where the question is no longer which single therapy works best, but how treatments can be combined to improve outcomes. Across oncology, resistance and relapse remain persistent challenges, and the industry’s response has been increasingly clear: multi-drug regimens targeting different biological pathways are delivering results that single agents cannot.

• Targeted cancer therapies are increasingly being paired with immunotherapy and chemotherapy to improve outcomes across multiple tumor types
• First-in-class PP2A inhibitor LB-100 is designed to enhance treatment response by disrupting cancer cell repair mechanisms and boosting immune activity
• Ongoing clinical trials are exploring LB-100 across solid tumors, including ovarian and colorectal cancers, where unmet need remains high

Lixte Biotechnology Holdings Inc. (NASDAQ: LIXT) is advancing a first-in-class compound designed to fit directly into that model. Rather than developing a standalone therapy, the company is focused on enhancing the effectiveness of existing treatments, specifically chemotherapy and…

Read More

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

Forward Looking Statements

Certain statements in this article are forward-looking, as defined in the Private Securities Litigation Reform Act of 1995. These statements involve risks, uncertainties, and other factors that may cause actual results to differ materially from the information expressed or implied by these forward-looking statements and may not be indicative of future results. These forward-looking statements are subject to a number of risks and uncertainties, including, among others, various factors beyond management's control, including the risks set forth under the heading "Risk Factors" discussed under the caption "Item 1A. Risk Factors" in Part I of the Company's most recent Annual Report on Form 10-K or any updates discussed under the caption "Item 1A. Risk Factors" in Part II of the Company's Quarterly Reports on Form 10-Q and in the Company's other filings with the SEC. Undue reliance should not be placed on the forward-looking statements in this article in making an investment decision, which are based on information available to us on the date hereof. All parties undertake no duty to update this information unless required by law

This contant was orignally distributed by NewMediaWire. Blockchain Registration, Verification & Enhancement provided by NewsRamp™. The source URL for this press release is Precision Oncology Is Shifting Toward Combination Strategies, Ultimately Changing How New Therapies Are Built.